Solopass System for Hydrocephalus

This trial tests the Solopass System, designed to assist individuals with hydrocephalus, a condition characterized by excess fluid accumulation in the brain. The trial aims to determine if this system can accurately place a drain to remove the fluid, minimizing the need for multiple attempts or errors. It targets individuals recently diagnosed with hydrocephalus, currently in a Neuro ICU, and with a recent CT scan indicating that more than half of the fluid is cerebrospinal fluid (CSF) rather than blood.

As an unphased trial, this study provides patients the chance to contribute to innovative research that could enhance treatment options for hydrocephalus.

The trial information does not specify whether you need to stop taking your current medications. However, it does mention that participants should not have an active infection or be on antibiotics.

Research has shown that the Solopass System is under study for its safety in brain-related medical procedures. Although clinical trials have not provided extensive direct safety data specifically for this system, the FDA has cleared the Solopass 2.0, indicating it meets certain safety standards for medical use.

In other research involving similar systems, such as the eShunt System, scientists have monitored safety by observing any unwanted effects. While these studies do not directly involve the Solopass System, they emphasize a focus on ensuring patient safety in similar technologies used to treat hydrocephalus, a condition where fluid accumulates in the brain.

Unlike traditional treatments for hydrocephalus, which often involve manually positioning catheters, the Solopass System uses an advanced guided method to assist with catheter placement. This innovative approach aims to enhance precision and reduce human error during the procedure. Researchers are excited about this system because it has the potential to improve patient outcomes by ensuring more accurate placement, which could lead to fewer complications and better management of hydrocephalus.

Research has shown that the Solopass System aims to improve the accuracy of external ventricular drain placement in patients with hydrocephalus. In this trial, doctors will use the Solopass System during catheter placement, guiding the procedure with real-time ultrasound imaging to reduce mistakes and complications. Although specific data on Solopass's effectiveness in humans is limited, this method aligns with general trends toward safer and more effective neurosurgery. Less invasive techniques, such as Solopass, are gaining popularity due to their potential to enhance patient care. Overall, the system is designed to make the procedure safer and more precise.³⁵⁶⁷⁸